Lilly CEO Ricks scores big pay bump to $21.3M by Eric Sagonowsky Wednesday, March 18, 2020 Eli Lilly has refocused around new medicines and met many of its compensation targets in 2019, the company said in a proxy filing.
Lilly planning 'top-tier' growth to 2025 thanks to new launches by Eric Sagonowsky Thursday, January 30, 2020 Lilly's new meds are picking up steam, generating nearly half of the company's Q4 sales. And it's looking to three potential rollouts later this year.
Lilly inks $1.1B Dermira deal as biopharma M&A gets underway by Arlene Weintraub Friday, January 10, 2020 Eli Lilly's $1.1 billion Dermira bid is smart, some analysts say, because it brings in both a marketed drug and a phase 3 atopic dermatitis asset.
CEO urges patients to get Lilly's help paying for insulin by Eric Sagonowsky Thursday, December 19, 2019 After senators criticized Eli Lilly on insulin affordability this week, CEO David Ricks called their report “nonsense." But now he's changed his tune.
Senators blast Lilly's insulin generic, but CEO Ricks hits back by Eric Sagonowsky Wednesday, December 18, 2019 A report from two senators concluded Eli Lilly's insulin generic has failed patients, but Lilly CEO David Ricks called that idea "nonsense."
Big Pharma CEOs' Chinese names: What they mean by Angus Liu Tuesday, October 1, 2019 Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
Lilly chief David Ricks picks up 9% raise to $17.2M by Eric Sagonowsky Wednesday, March 13, 2019 Lilly CEO David Ricks, in his second year on the job, hauled in a pay package larger than those of a few of his big pharma peers.
Lilly answers price-hike critics with 50% off generic Humalog by Angus Liu Monday, March 4, 2019 The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.
Big Pharma CEOs give thumbs-up to Trump's rebate overhaul by Eric Sagonowsky Thursday, February 7, 2019 Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.
